Oncomed Offers Data from Phase 1a Trial of OMP-52M51 in Oral Plenary Session
November 19, 2014 at 07:53 AM EST
OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells ...